Mergers & Acquisitions ·
BioMarin expects $1.50 Q3 EPS hit from $283M Alesta IPR&D charge
BMRNBiomarin Pharmaceutical Inc
BioMarin estimates its third-quarter 2026 GAAP and non-GAAP diluted earnings per share will decrease by approximately $1.50 due to a $283 million pre-tax acquired in-process research and development (IPR&D) expense related to the August acquisition of Alesta Therapeutics. The company anticipates total full-year 2026 pre-tax charges of roughly $320 million, representing an unfavorable impact of about $1.55 per share, as it prepares updated guidance for the remainder of the year. BioMarin is a biopharmaceutical company focused on discovering and developing innovative therapies for rare genetic diseases.